Novavax to submit COVID-19 vaccine to FDA for approval
Novavax plans to apply for FDA authorization of its two shot COVID-19 vaccine in the U.S. during the third quarter of this year. The biotech company released late-stage study results Monday, showing it's vaccine had 90 percent efficacy even with many variants of the virus.
www.oann.com
